Celularity Inc. (NASDAQ:CELU – Get Rating) was the target of a large drop in short interest in July. As of July 31st, there was short interest totalling 2,670,000 shares, a drop of 11.9% from the July 15th total of 3,030,000 shares. Based on an average trading volume of 621,500 shares, the days-to-cover ratio is presently 4.3 days. Approximately 7.4% of the shares of the stock are short sold.
Analyst Upgrades and Downgrades
Separately, HC Wainwright assumed coverage on Celularity in a research report on Wednesday, June 22nd. They set a “buy” rating for the company.
Hedge Funds Weigh In On Celularity
Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC raised its position in shares of Celularity by 28.3% during the first quarter. Jane Street Group LLC now owns 16,813 shares of the company’s stock worth $146,000 after purchasing an additional 3,713 shares during the period. Citigroup Inc. bought a new position in shares of Celularity in the 1st quarter valued at about $36,000. HighMark Wealth Management LLC bought a new stake in Celularity in the first quarter valued at approximately $29,000. UBS Group AG boosted its position in Celularity by 177.6% during the second quarter. UBS Group AG now owns 10,300 shares of the company’s stock worth $36,000 after purchasing an additional 6,590 shares during the period. Finally, American International Group Inc. acquired a new stake in Celularity during the 2nd quarter worth approximately $25,000. 12.13% of the stock is owned by institutional investors.
Celularity Price Performance
Celularity (NASDAQ:CELU – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.25). Celularity had a net margin of 122.50% and a negative return on equity of 11.34%. The business had revenue of $5.94 million during the quarter, compared to the consensus estimate of $5.16 million. As a group, equities analysts expect that Celularity will post -1.04 EPS for the current fiscal year.
Celularity Company Profile
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
- Get a free copy of the StockNews.com research report on Celularity (CELU)
- Lowe’s Stands Out Amid Q2 Retail Reports
- Agilent Technologies Proves Its Worth VS Illumina
- Target’s Results Cap Upside Potential For Retail Stocks
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.